ArticleBMC complementary medicine and therapies2025
Antioxidant and hepatoprotective effect of Jatropha dioica against the valproic acid-induced damage in an in vivo model.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding liver diseases is important worldwide due to their prevalence. Apart from liver disease arising from hepatitis C viral infection, most chronic liver diseases currently have no cure. Several therapeutic alternatives, including some natural products, have been proposed to treat liver diseases. The natural product Jatropha dioica has been reported to possess antioxidant activity and, by extension, could have hepatoprotective activity. Accordingly, our aim was to test the hypothesis that an extract of J. dioica is protective against liver damage induced by valproic acid (VPA).
methodsTwelve male and twelve female Wistar rats were sorted into four groups: control, non-toxicity, valproic acid control (VPA-C), and J. dioica + VPA (JdVPA). J. dioica (300 mg/kg, given orally) was used as treatment, followed by a concomitant injection of VPA (500 mg/kg, i.p.) for the first 4 days to induce liver injury. To evaluate the severity of the injury, liver function tests were performed. In addition, oxidative stress biomarkers were quantified, as well as measures of the expression of the genes Actb, Il6, and Nfkb1.
resultsThe VPA-C group showed a significant increase in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and malondialdehyde (MDA), a decrease in superoxide dismutase (SOD), and a reduction in glutathione (GSH) vs the control group. The JdVPA group showed a significant decrease in ALT, AST, and MDA and an increase in GSH and SOD vs the VPA-C group. Gene expression of Il6 and Nfkb1 did not show any statistically significant differences between study groups. Histologically, VPA presented an inflammatory infiltrate, which decreased in the JdVPA group.
conclusionThe extract of J. dioica at the administered dose did not display toxicity and was capable of ameliorating the liver injury generated by VPA in biochemical and oxidative stress biomarkers, which suggests its potential hepatoprotective activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.